In an early June press release Oxford Biomedica, plc (LSE: OXB), announced the company’s voluntarily suspension of patient recruitment for their RetinoStat Phase I, StarGen Phase I/IIa and UshStat Phase I/IIa clinical trials. The company stated that the action was a precautionary measure, while investigations were underway following the detection of potential impurities derived from what was referred to as a “widely-used third party raw material”. The company made no comment on the specifics of the impurity or on their suspected source but did state that, “there were no safety concerns identified in preclinical or clinical testing of the products and there is no reason to believe that the safety profile of the products will be affected”.
UK-based Oxford Biomedica, plc, suspends patient enrolment in 3 ophthalmic clinical trials due to detection of impurities in raw material
- by swdadmin